Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn’s Disease Therapeutic Outcomes Assessed Clinically and Endoscopically
Emily K. Wright, María Chaparro, Paolo Gionchetti, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 2, pp. 212-222
Closed Access | Times Cited: 7

Showing 7 citing articles:

Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease
Andrés Yarur, Thierry Dervieux, Ryan C. Ungaro, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 187-187
Open Access
Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn’s Disease
J L Rueda García, Cristina Suárez Ferrer, Clara Amiama Roig, et al.
Therapeutic Advances in Gastroenterology (2025) Vol. 18
Open Access
Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
Tina Deyhim, Adam S. Cheifetz, Konstantinos Papamichael
Journal of Clinical Medicine (2023) Vol. 12, Iss. 22, pp. 7132-7132
Open Access | Times Cited: 12
“Getting the Dose Right”—Revisiting the Topic With Focus on Biologic Agents
Diane R. Mould, Richard N. Upton
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 613-618
Closed Access | Times Cited: 3
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α
Elizabeth Spencer, Marla C. Dubinsky, Michael A. Kamm, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
SERENE ER Analysis Part 2 SERENE‐UC: Exposure‐response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis
Sven Stodtmann, Mong‐Jen Chen, Ana Victoria Ponce Bobadilla, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 9, pp. 1033-1043
Closed Access | Times Cited: 1
SERENE ER Analysis Part 1‐SERENE CD: Exposure‐Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease
Mong‐Jen Chen, Ana Victoria Ponce Bobadilla, Sven Stodtmann, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 9, pp. 1024-1032
Closed Access | Times Cited: 1
Page 1

Scroll to top